Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Open Access
- 22 May 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 3 (3) , e000515
Abstract
Background: Signals of an increased risk of myocardial infarction ( MI ) have been identified with dabigatran etexilate in randomized controlled trials ( RCTs ). Methods and Resules: We conducted searches of the published literature and a clinical trials registry maintained by the drug manufacturer. Criteria for inclusion in our meta‐analysis included all RCT s and the availability of outcome data for MI , other cardiovascular events, major bleeding, and all‐cause mortality. Among the 501 unique references identified, 14 RCT s fulfilled the inclusion criteria. Stratification analyses by comparators and doses of dabigatran etexilate were conducted. Peto odds ratio ( OR PETO ) values using the fixed‐effect model ( FEM ) for MI , other cardiovascular events, major bleeding, and all‐cause mortality were 1.34 (95% CI 1.08 to 1.65, P =0.007), 0.93 (95% CI 0.83 to 1.06, P =0.270), 0.88 (95% CI 0.79 to 0.99, P =0.029), and 0.89 (95% CI 0.80 to 1.00, P =0.041). When compared with warfarin, OR PETO values using FEM were 1.41 (95% CI 1.11 to 1.80, P =0.005), 0.94 (95% CI 0.83 to 1.06, P =0.293), 0.85 (95% CI 0.76 to 0.96, P =0.007), and 0.90 (95% CI 0.81 to 1.01, P =0.061), respectively. In RCT s using the 150‐mg BID dosage, the OR PETO values using FEM were 1.45 (95% CI 1.11 to 1.91, P =0.007), 0.95 (95% CI 0.82 to 1.09, P =0.423), 0.92 (95% CI 0.81 to 1.05, P =0.228), and 0.88 (95% CI 0.78 to 1.00, P =0.045), respectively. The results of the 110‐mg BID dosage were mainly driven by the RE ‐ LY trial. Conclusions: This meta‐analysis provides evidence that dabigatran etexilate is associated with a significantly increased risk of MI . This increased risk should be considered taking into account the overall benefit in terms of major bleeding and all‐cause mortality.Keywords
This publication has 53 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trialsBMJ Open, 2012
- Contribution of the -160C/A Polymorphism in the E-cadherin Promoter to Cancer Risk: A Meta-Analysis of 47 Case-Control StudiesPLOS ONE, 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- Antithrombotic Therapy for Atrial FibrillationChest, 2012
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996